Advertisement
Canada markets closed

  • S&P/TSX

    24,822.54
    +132.06 (+0.53%)
     

  • S&P 500

    5,864.67
    +23.20 (+0.40%)
     

  • DOW

    43,275.91
    +36.86 (+0.09%)
     

  • CAD/USD

    0.7246
    -0.0004 (-0.05%)
     

  • CRUDE OIL

    69.34
    -1.33 (-1.88%)
     

  • Bitcoin CAD

    94,401.95
    +512.88 (+0.55%)
     

  • XRP CAD

    0.75
    +0.00 (+0.20%)
     

  • GOLD FUTURES

    2,736.40
    +28.90 (+1.07%)
     

  • RUSSELL 2000

    2,276.09
    -4.76 (-0.21%)
     

  • 10-Yr Bond

    4.0730
    -0.0230 (-0.56%)
     

  • NASDAQ

    18,489.55
    +115.94 (+0.63%)
     

  • VOLATILITY

    18.03
    -1.08 (-5.65%)
     

  • FTSE

    8,358.25
    -26.88 (-0.32%)
     

  • NIKKEI 225

    38,981.75
    +70.56 (+0.18%)
     

  • CAD/EUR

    0.6666
    -0.0024 (-0.36%)
     

Dexcom shares crash nearly 40% as execution miss drives 2024 guidance cut

Investing.com
·2 min read

Investing.com -- Dexcom slashed its guidance Thursday after reporting second-quarter revenue fell short of estimates as the diabetes management solutions provider flagged weaker execution of key strategies.

DexCom Inc (NASDAQ:DXCM) fell more than 37% in premarket trading Friday.

The company now expects revenue of approximately $4.00B to $4.05B for the fiscal 2024, down from prior guidance of $4.20B to $4.35B.

"While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards," the company said.

The company reported Q2 earnings $0.43 per share on revenue of $1.00 billion, compared with estimates of $0.39 on revenue of $1.04B.

For Q3, revenue was guided in a range of $ $975M to $1.00B, missing analyst estimates of $1.15B.

"There’s no getting away from the fact that this Thursday’s update was a sharp turn in the wrong direction for Dexcom," JPMorgan analysts said in a note.

"We expect shares will struggle to outperform as it navigates these near-term challenges and works to rebuild investor trust," analysts added, downgrading the DXCM stock from Overweight to Neutral and nearly halving the price target from $145 to $75.

"While we still walked away from earnings with some unanswered questions, we feel very confident that this is due to multiple self-inflicted issues rather than a market growth issue. The TAM is substantial and the opportunity remains for the long-term."

Meanwhile, comments from RBC analysts were notably less negative. While acknowledging that the execution miss was "disappointing," the investment bank believes the near 40% sell-off in the stock "is unjustified."

"We are buyers on weakness," RBC added, maintaining an Outperform rating but trimming the target price from $165 to $145.

Yasin Ebrahim contributed to this report.

Related Articles

Dexcom shares crash nearly 40% as execution miss drives 2024 guidance cut

EssilorLuxottica powers European shares; benchmark set for weekly gain

Nvidia supplier SK Hynix to invest $6.8 billion in South Korea chip plant